Psychedelics as Therapy: What Causes Negative Outcomes?

12 Apr

Over the past decade, scientific and clinical interest in psychedelics such as psilocybin, LSD, and ayahuasca has risen exponentially. A growing body of research suggests potential therapeutic applications for conditions including depression, anxiety, post-traumatic stress disorder (PTSD), and substance use disorders 111. Nevertheless, as with any powerful intervention, risks remain. While many patients and participants report positive or transformative experiences, negative outcomes—including severe anxiety, paranoia, or even psychotic episodes—can occur. This article discusses the potential mechanisms behind these adverse events, focusing on patient predisposition, psychological context, and the physiological profiles of psychedelics in therapeutic settings.

1. Overview of Psychedelics as Therapeutic Agents

Classic Psychedelics and Their Mechanisms

Classic psychedelics primarily work as partial agonists at serotonin 5-HT2A receptors, which induce alterations in perception, cognition, and emotion 222. When combined with supportive clinical settings, these altered states can facilitate introspection and emotional processing that may improve mental health outcomes 333. Recent clinical studies have demonstrated psilocybin’s efficacy for treatment-resistant depression 444 and end-of-life anxiety 555, while ayahuasca ceremonies have shown potential to address mood disorders 666.

A Growing Clinical Landscape

The resurgence in clinical trials has led to innovative therapy models, often involving the administration of a psychedelic substance in conjunction with psychotherapy. While preliminary results have been promising, there is a non-trivial risk that some participants may experience lasting negative psychological or physiological sequelae, underscoring the importance of understanding the mechanisms that drive such outcomes 1,31,31,3.

2. Risk Factors for Negative Outcomes

Psychological Vulnerabilities and Psychopathology

Pre-existing Mental Health Conditions: Individuals with a personal or family history of psychosis (e.g., schizophrenia), bipolar disorder, or borderline personality traits may be especially prone to adverse experiences. Psychedelic-induced dissociation or emotional volatility can aggravate these underlying vulnerabilities 777.
Inadequate Screening: A comprehensive psychiatric evaluation is critical. In settings where screening is lax, individuals with undiagnosed conditions may be exposed to a potentially destabilizing experience 888.

Set and Setting

Set (Mindset): Expectations, mood, and emotional state prior to the session can strongly influence the psychedelic experience. High anxiety or external stress can predispose participants to challenging experiences or panic responses 999.
Setting (Environment): A calm, supportive environment is vital for minimizing adverse outcomes. Noise, bright lights, unpredictable interruptions, or unsupportive facilitators can exacerbate fear or disorientation 101010.

Pharmacological Interactions

Concurrent Medications: SSRIs, MAOIs, and other psychiatric medications can interact with psychedelics, potentially increasing serotonergic effects or amplifying anxiety responses 222.
Substance Use: Combining psychedelics with alcohol or stimulants, for example, can heighten psychological distress and cardiovascular stress, increasing the likelihood of an adverse event 111111.

Dosing Variables

Dose Response: Psychedelics often exhibit a steep dose-response curve. Going from a moderate to a high dose can radically intensify the experience and potential adverse effects 121212.
Purity and Composition: In non-clinical settings, substances labeled “psychedelic” may be adulterated or mislabeled, heightening the risk of unexpected pharmacological effects 131313.

3. Common Negative Outcomes

Acute Psychological Reactions

Panic and Paranoia: Many so-called “bad trips” are marked by terror, feelings of losing control, or paranoia. While often transient, such experiences can be severe if not managed properly 141414.
Dysphoria: Some individuals may develop a profound sense of despair or hopelessness during the experience, potentially triggering a worsening of underlying depressive symptoms.

Longer-Term Aftereffects

Persistent Psychosis: Though rare, prolonged psychotic episodes have been reported in vulnerable individuals. These incidents can resemble acute schizophrenia-like conditions 777.
Hallucinogen Persisting Perception Disorder (HPPD): A poorly understood condition in which users experience prolonged or recurring perceptual disturbances even after the drug has worn off 151515.
Mood Instability: Residual emotional lability can last for days or weeks in some cases, particularly if the experience was profoundly distressing 161616.

4. Strategies to Mitigate Risk

Rigorous Screening and Preparation

Clinical Assessment: Exclude individuals with a history of severe psychiatric disorders, especially psychosis or mania. Confirm that current medications do not pose significant contraindications 888.
Psychoeducation: Prepare participants through counseling and education about possible experiences, coping strategies, and what to expect 999.

Supportive Therapeutic Environment

Trained Facilitators: Ensure psychotherapists or guides are experienced in managing challenging psychedelic experiences, equipped to calm and reassure participants 101010.
Controlled Setting: A safe, private, and calm environment, away from loud noises or potential stressors, can significantly reduce the chances of acute panic 333.

Aftercare and Integration

Integration Sessions: Post-experience psychotherapy or counseling can help individuals process challenging experiences, reducing the potential for lingering distress 555.
Follow-Up: Regular check-ins allow healthcare providers to monitor mental status and intervene promptly if adverse effects arise.

5. Future Directions

Despite promising therapeutic outcomes in studies, we still lack long-term safety data for various subpopulations. Ongoing research, larger sample sizes, and randomized controlled trials are needed to clarify the exact incidence of negative outcomes, identify high-risk groups more precisely, and optimize harm reduction strategies. Development of standardized training protocols for therapists and facilitators will also remain crucial as interest in psychedelic therapies grows 1,31,31,3.

Psychedelics hold significant therapeutic promise, but they also carry meaningful risks. Negative outcomes can be influenced by a complex interplay of individual psychological factors, environmental contexts, and pharmacological mechanisms. Through careful screening, supportive set and setting, and ongoing integration, researchers and clinicians can help reduce the incidence of these adverse events. As the field continues to evolve, further research is essential to refine these approaches and ensure that psychedelic-assisted therapy remains both efficacious and safe for those who can benefit from it.

References

Nutt, D., Erritzoe, D., & Carhart-Harris, R. (2020). Psychedelic psychiatry’s brave new world. Cell, 181(1), 24–28.
Nichols, D. E. (2016). Psychedelics. Pharmacological Reviews, 68(2), 264–355.
Carhart-Harris, R. L., & Goodwin, G. M. (2017). The therapeutic potential of psychedelic drugs: Past, present, and future. Neuropsychopharmacology, 42(11), 2105–2113.
Carhart-Harris, R. L. et al. (2016). Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. The Lancet Psychiatry, 3(7), 619–627.
Griffiths, R. R., et al. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology, 30(12), 1181–1197.
Osório, F. de L., et al. (2015). Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: A preliminary report. Revista Brasileira de Psiquiatria, 37(1), 13–20.
Ross, S., et al. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. Journal of Psychopharmacology, 30(12), 1165–1180.
888 Johnson, M. W., Griffiths, R. R., & Hendricks, P. S. (2019). Human hallucinogen research: Guidelines for safety. Journal of Psychopharmacology, 33(9), 1021–1027.
Hartogsohn, I. (2016). Set and setting, psychedelics and the placebo response: An extra-pharmacological perspective on psychopharmacology. Journal of Psychopharmacology, 30(12), 1259–1267.
Johnson, M. W., Richards, W. A., & Griffiths, R. R. (2008). Human hallucinogen research: guidelines for safety, best practices, and efficacy. Journal of Psychopharmacology, 22(6), 603–620.
Halpern, J. H. (2004). Hallucinogens and dissociative agents naturally growing in the United States. Pharmacology & Therapeutics, 102(2), 131–138.
Strassman, R. (2001). DMT: The spirit molecule. Park Street Press.
Kripal, J. J. (2020). Secret body: Erotic and esoteric currents in the history of religions. The University of Chicago Press (Discussion on non-clinical contexts).
Barrett, F. S., Bradstreet, M. P., Leoutsakos, J.-M., Johnson, M. W., & Griffiths, R. R. (2016). The challenging experience questionnaire: Characterization of challenging experiences with psilocybin mushrooms. Journal of Psychopharmacology, 30(12), 1279–1295.
Martinotti, G., et al. (2018). Hallucinogen persisting perception disorder: Etiology, clinical features, and therapeutic perspectives. Brain Sciences, 8(3), 47.
Carbonaro, T. M., Johnson, M. W., Hurwitz, E., & Griffiths, R. R. (2018). Double-blind comparison of the two doses of psilocybin in healthy human volunteers. Journal of Psychopharmacology, 32(7), 725–736.

Disclaimer: This article is for educational purposes only and is not a substitute for professional medical or legal advice. If you have questions regarding the use of psychedelics or mental health concerns, please consult a qualified healthcare professional.

Justin Wood